Product
CMC-544
1 clinical trial
1 indication
Indication
Acute Lymphoblastic LeukemiaClinical trial
Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) With CMC-544 (Inotuzumab Ozogamycin), With or Without Later Addition of RituximabStatus: Completed, Estimated PCD: 2018-04-18